US2004001826A1PendingUtilityA1

Glycoprotein VI and uses thereof

50
Assignee: MILLENNIUM PHARM INCPriority: Jun 30, 1999Filed: Apr 9, 2001Published: Jan 1, 2004
Est. expiryJun 30, 2019(expired)· nominal 20-yr term from priority
Inventors:Davinder GillMing Qian
C07K 16/2803C07K 2317/622C07K 2317/565C07K 14/705C07K 2319/00A61K 38/00C07K 16/28
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides isolated nucleic acid molecules and polypeptide molecules that encode glycoprotein VI, a platelet membrane glycoprotein that is involved platelet-collagen interactions. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A substantially purified antibody comprising a variable heavy (VH) complementarity determining region (CDR)1 having an amino acid sequence of SEQ ID NO:49 or 73, wherein said antibody immunospecifically binds to a TANGO 268 antigen.  
     
     
         2 . A substantially purified antibody comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:50 or 74, wherein said antibody immunospecifically binds to a TANGO 268 antigen.  
     
     
         3 . A substantially purified antibody comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:51 or 75, wherein said antibody immunospecifically binds to a TANGO 268 antigen.  
     
     
         4 . A substantially purified antibody comprising a variable light (VL) CDR1 having an amino acid sequence of SEQ ID NO:52 or 76, wherein said antibody immunospecifically binds to a TANGO 268 antigen.  
     
     
         5 . A substantially purified antibody comprising a VL CDR2 having an amino acid sequence of SEQ ID NO:53 or 77 antibody immunospecifically binds to a TANGO 268 antigen.  
     
     
         6 . A substantially purified antibody comprising a VL CDR3 having an amino acid sequence of SEQ ID NO:54 or 78, wherein said antibody immunospecifically binds to a TANGO 268 antigen.  
     
     
         7 . The antibody of  claim 1  further comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:50, 56, 62, 68 or 74.  
     
     
         8 . The antibody of  claim 1  further comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:51, 57, 63, 69 or 75.  
     
     
         9 . The antibody of  claim 1  further comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:50, 56, 62, 68 or 74 and a VH CDR3 having an amino acid sequence of SEQ ID NO:51, 57, 63, 69 or 75.  
     
     
         10 . The antibody of  claim 1  further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64, 70 or 76.  
     
     
         11 . The antibody of  claim 1  further comprising a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65, 71 or 77.  
     
     
         12 . The antibody of  claim 1  further comprising a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66, 72 or 78.  
     
     
         13 . The antibody of  claim 1  further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64, 70 or 76, a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65, 71 or 77, and a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66, 72 or 78.  
     
     
         14 . The antibody of  claim 7 ,  8  or  9  further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64, 70 or 76.  
     
     
         15 . The antibody of  claim 7 ,  8  or  9  further comprising a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65, 71 or 77.  
     
     
         16 . The antibody of  claim 7 ,  8  or  9  further comprising a VL CDR3 having an amino acid sequence of SEQ ID NO: 54, 60, 66, 72 or 78.  
     
     
         17 . The antibody of  claim 7  or  8  further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64, 70 or 76, a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65, 71 or 77, and a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66, 72 or 78.  
     
     
         18 . The antibody of  claim 9  further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64, 70 or 76, a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65, 71 or 77, and a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66, 72 or 78.  
     
     
         19 . The antibody of  claim 2  further comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:50, 56, 62, 68 or 75.  
     
     
         20 . The antibody of  claim 2  further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64, 70 or 76.  
     
     
         21 . The antibody of  claim 2  further comprising a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65, 71 or 77.  
     
     
         22 . The antibody of  claim 2  further comprising a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66, 72 or 73.  
     
     
         23 . The antibody of  claim 2  further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64, 70 or 76, a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65, 71 or 77, and a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66, 72 or 78.  
     
     
         24 . The antibody of  claim 19  further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64, 70 or 76, a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65, 71 or 77, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 54, 60, 66, 72 or 78.  
     
     
         25 . The antibody of  claim 3  further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64, 70 or 76.  
     
     
         26 . The antibody of  claim 3  further comprising a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65, 71 or 77.  
     
     
         27 . The antibody of  claim 3  further comprising a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66, 72 or 78.  
     
     
         28 . The antibody of  claim 3  further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64, 70 or 76, a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65, 71 or 77, and a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66, 72 or 78.  
     
     
         29 . A Fab fragment of a mouse monoclonal antibody produced by the mouse hybridoma cell line 9012.2, 1P10.2, 8M14.3, 9E18.2 or 744.6 deposited with the ATCC® as patent deposit Number PTA-1746, patent deposit Number PTA-1747, patent deposit Number PTA-1748, patent deposit Number PTA-1749 or patent deposit Number PTA-1750.  
     
     
         30 . An antibody that competes for binding to a TANGO 268 antigen with the scFv clone A4, A9, A10 or C3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445.  
     
     
         31 . An antibody that competes for binding to a TANGO 268 antigen with the mouse monoclonal antibody produced by the mouse hybridoma cell line 9012.2, 1P10.2, 8M14.3, 9E18.2 or 744.6 deposited with the ATCC® as patent deposit Number PTA-1746, patent deposit Number PTA-1747, patent deposit Number PTA-1748, patent deposit Number PTA-1749 or patent deposit Number PTA-1750.  
     
     
         32 . The antibody as in any one of claims  1 - 6 ,  9 ,  13 ,  18 ,  23 ,  24 ,  28 ,  30  or  31 , wherein the antibody is a monoclonal antibody.  
     
     
         33 . The antibody as in any one of claims  1 - 6 ,  9 ,  13 ,  18 ,  23 ,  24 ,  28 ,  30  or  31 , wherein the antibody is a hum an antibody.  
     
     
         34 . The antibody as in any one of claims  1 - 6 ,  9 ,  13 ,  18 ,  23 ,  24 ,  28 ,  30  or  31 , wherein the antibody is a humanized antibody.  
     
     
         35 . The antibody as in any one of claims  1 - 6 ,  9 ,  13 ,  18 ,  23 ,  24 ,  28 ,  30  or  31 , wherein the antibody is a Fab fragment.  
     
     
         36 . The antibody as in any one of claims  1 - 6 ,  9 ,  13 ,  18 ,  23 ,  24 ,  28 ,  30  or  31 , wherein the antibody is an scFv.  
     
     
         37 . The antibody as in any one of claims  1 - 6 ,  9 ,  13 ,  18 ,  23 ,  24 , or  28 - 31 , wherein the antibody is conjugated to a therapeutic or drug moiety.  
     
     
         38  The antibody as in any one of claims  1 - 6 ,  9 ,  13 ,  18 ,  23 ,  24 , or  28 - 31 , wherein the antibody is conjugated to a detectable substance.  
     
     
         39 . A pharmaceutical composition comprising an antibody as in any one of claims  1 - 6 ,  9 ,  13 ,  18 ,  23 ,  24 , or  28 - 31 , and a pharmaceutically acceptable carrier.  
     
     
         40 . A pharmaceutical composition comprising an antibody as in  claim 37 , and a pharmaceutically acceptable carrier.  
     
     
         41 . A kit comprising an antibody as in any one of claims  1 - 6 ,  9 ,  13 ,  18 ,  23 ,  24 , or  28 - 31  and instructions for use, in one or more containers.  
     
     
         42 . A kit comprising an antibody as in  claim 38  and instructions for use, in one or more containers.

Join the waitlist — get patent alerts

Track US2004001826A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.